AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaporation drying
Number of subjects: 15
Study 16989023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib (0.3 mg injected into the eye every 6 weeks)
Number of subjects: 1208
Study 16989023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208
Study 16989023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib
Number of subjects: 1208
Study 12925219 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐methyl‐L‐arginine
Number of subjects: 0
Study 12925219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,2'‐dipyridyl
Number of subjects: 0
Study 12925219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide and reactive oxygen species
Number of subjects: 0
Study 11032267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (CIS)
Number of subjects: 40
Study 11032267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (ROC)
Number of subjects: 40
Study 11032267 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium (CIS) and Rocuronium (ROC)
Number of subjects: 40
Study 9296229 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MIC regimen (cisplatin 100 mg/m2 on day 2, ifosfamide on day 1 with mitomycin)
Number of subjects: 70
Study 9296229 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MIC regimen
Number of subjects: 70
Study 9296229 — intervention group
Group type: COMPARATOR
Intervention: Previous MIC regimen (cisplatin 120 mg/m2 on day 1)
Number of subjects: 70
Study 8337736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 to 200 micrograms/kg body weight)
Number of subjects: 55
Study 8337736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3550035 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing combined with antiformin-citric acid chemical curettage (SRP/AF)
Number of subjects: 10
Study 3550035 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (SRP)
Number of subjects: 10
Study 29573894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopically aided reductions
Number of subjects: 63
Study 29573894 — intervention group
Group type: COMPARATOR
Intervention: Standard reductions
Number of subjects: 63
Study 24721668 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes patients
Number of subjects: 398
Study 24721668 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 398
Study 24721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diabetes groups
Number of subjects: 398
Study 24721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fractures
Number of subjects: 398
Study 23245394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 216
Study 23245394 — intervention group
Group type: COMPARATOR
Intervention: Non bivalirudin-based anticoagulants
Number of subjects: 216
Study 21175545 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 120 µg/day
Number of subjects: 20
Study 21175545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 21175545 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 20
Study 18410283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (12.5 mg three times per day for 2 days)
Number of subjects: 24
Study 18410283 — intervention group
Group type: COMPARATOR
Intervention: Albumin (8 g/L of removed ascites)
Number of subjects: 24
Study 18410283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 24
Study 18410283 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 24
Study 15725319 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (A)
Number of subjects: 80
Study 15725319 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 80
Study 15725319 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-midazolam (RM)
Number of subjects: 80
Study 15725319 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-midazolam (AM)
Number of subjects: 80
Study 15725319 — intervention group
Group type: COMPARATOR
Intervention: Control (all groups)
Number of subjects: 80
Study 12887341 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips/Jordan HP 735 powered brush
Number of subjects: 80
Study 12887341 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B40+ manual brush
Number of subjects: 80
Study 10189005 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 45
Study 10189005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10189005 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker withdrawal (24 hours after discontinuation of metoprolol)
Number of subjects: 45
Study 8531308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg
Number of subjects: 56
Study 8531308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 56
Study 8531308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 56
Study 8531308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1861932 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at 0, 3, and 6 mg/kg per day for 3 months
Number of subjects: 334
Study 1861932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 1861932 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation and placebo
Number of subjects: 334
Study 6342354 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus dipyridamole (400 mg/day)
Number of subjects: 534
Study 6342354 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin (500 mg/day)
Number of subjects: 534
Study 6342354 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 534
Study 30660549 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic texture analysis (TA) on quantitative cardiovascular magnetic resonance images
Number of subjects: 232
Study 30660549 — intervention group
Group type: COMPARATOR
Intervention: Global native T1 mapping
Number of subjects: 232
Study 30496458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (replacing ethambutol in the standard regimen)
Number of subjects: 126
Study 30496458 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (including pyrazinamide and rifampicin)
Number of subjects: 126
Study 30496458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (with peak concentration above 7 mg/L)
Number of subjects: 126
Study 26305114 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional descriptive information about behaviour corresponding to BPD with explicit mention of BPD as a possible comorbid diagnostic label
Number of subjects: 265
Study 26305114 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional descriptive information about behaviour corresponding to BPD
Number of subjects: 265
Study 26305114 — intervention group
Group type: EXPERIMENTAL
Intervention: General background information
Number of subjects: 265
Study 25320199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion group
Number of subjects: 46
Study 25320199 — intervention group
Group type: COMPARATOR
Intervention: Non-fusion group
Number of subjects: 46
Study 25320199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 22440499 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 μg/mm² balloon surface)
Number of subjects: 108
Study 22440499 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 108
Study 20350917 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 10
Study 20350917 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone
Number of subjects: 10
Study 20350917 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 10
Study 20350917 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (baseline)
Number of subjects: 10
Study 17470017 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment in group 2 (266 patients)
Number of subjects: 450
Study 17470017 — intervention group
Group type: COMPARATOR
Intervention: Healthy patients (group 1)
Number of subjects: 450
Study 17470017 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (62 patients dropped out)
Number of subjects: 450
Study 16001200 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 30
Study 16001200 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (200 microg)
Number of subjects: 30
Study 12067867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate bolus (LBB) group
Number of subjects: 44
Study 12067867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate groups
Number of subjects: 44
Study 12067867 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study 9854159 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied prior to UV treatment
Number of subjects: 5
Study 9854159 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied in combination with UV-radiation
Number of subjects: 5
Study 9854159 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet radiation (UV) of 254 nm wavelength
Number of subjects: 5
Study 9854159 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied after UV treatment
Number of subjects: 5
Study 7875472 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam (35 micrograms/kg) and lidocaine spray (100 mg)
Number of subjects: 200
Study 7875472 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and placebo lidocaine
Number of subjects: 200
Study 7875472 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo midazolam and lidocaine
Number of subjects: 200
Study 7875472 — intervention group
Group type: COMPARATOR
Intervention: placebo midazolam and placebo lidocaine
Number of subjects: 200
Study 2484856 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide
Number of subjects: 18
Study 2484856 — intervention group
Group type: COMPARATOR
Intervention: Quinidine plus digoxin
Number of subjects: 18
Study 213498 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-20,961 administered prior to challenge
Number of subjects: 60
Study 213498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 213498 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-20,961 administered 24 hours after challenge
Number of subjects: 60
Study 213498 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-20,961 administered 48 hours after challenge
Number of subjects: 60
Study 30145342 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 18
Study 30145342 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 18
Study 28701225 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 41
Study 25322869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupressure
Number of subjects: 120
Study 25322869 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120
Study 25322869 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 120
Study 23395191 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial skills training and health management program (Helping Older People Experience Success)
Number of subjects: 183
Study 23395191 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 183
Study 20800453 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-months vocational rehabilitation program
Number of subjects: 112
Study 20800453 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 112
Study 19154828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 hours of interdisciplinary rehabilitation a week
Number of subjects: 108
Study 19154828 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 hours of interdisciplinary rehabilitation a week
Number of subjects: 108
Study 19154828 — intervention group
Group type: COMPARATOR
Intervention: No active rehabilitation
Number of subjects: 108
Study 17763317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 127
Study 15754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust anisotropic Gaussian fitting for volumetric characterization of pulmonary nodules
Number of subjects: 1310
Study 15754991 — intervention group
Group type: COMPARATOR
Intervention: Gamma-normalized Laplacian approach (Linderberg, 1998)
Number of subjects: 1310
Study 15754991 — intervention group
Group type: COMPARATOR
Intervention: Standard sample estimation approach (Matei, 2001)
Number of subjects: 1310
Study 11809990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 12 (3) cm H2O for 40 minutes
Number of subjects: 12
Study 11809990 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) with flow assist 4.9 (1.3) cm H2O/l.s and volume assist 18.9 (5.1) cm H2O/l for 40 minutes
Number of subjects: 12
Study 11809990 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAV and PSV
Number of subjects: 12
Study 10206300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatinase-A in glioma specimens
Number of subjects: 53
Study 10206300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatinase-B transcript and activity levels
Number of subjects: 53
Study 10206300 — intervention group
Group type: EXPERIMENTAL
Intervention: MT1-MMP mRNA levels
Number of subjects: 53
Study 10206300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatinase-B expression
Number of subjects: 53
Study 8719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Gn-RHa plus hGH therapy
Number of subjects: 30
Study 8719441 — intervention group
Group type: COMPARATOR
Intervention: Gn-RHa alone (control group)
Number of subjects: 30
Study 2624987 — intervention group
Group type: EXPERIMENTAL
Intervention: Angong‐Niuhuang Pills (ANP)
Number of subjects: 104
Study 2624987 — intervention group
Group type: COMPARATOR
Intervention: Other medical treatment (Control)
Number of subjects: 104
Study 772973 — intervention group
Group type: EXPERIMENTAL
Intervention: Digilanid C
Number of subjects: 66
Study 772973 — intervention group
Group type: COMPARATOR
Intervention: Isolanid (Richter)
Number of subjects: 66
Study 31025363 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass AIT
Number of subjects: 95
Study 31025363 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch AIT
Number of subjects: 95
Study 31025363 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 95
Study 31025363 — intervention group
Group type: COMPARATOR
Intervention: Untargeted treatments
Number of subjects: 95
Study 27558412 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR) with greater widespread hyperalgesia and more severe OA (Grade 4 OA)
Number of subjects: 473
Study 27558412 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) with greater widespread hyperalgesia and less severe OA (Grade 3 OA)
Number of subjects: 473
Study 27558412 — intervention group
Group type: COMPARATOR
Intervention: Total Knee Replacement (TKR) with more severe OA (Grade 4 OA)
Number of subjects: 473
Study 27558412 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Replacement (THR) with more severe OA (Grade 4 OA)
Number of subjects: 473
Study 25284616 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of portal vein thrombosis (PVT)
Number of subjects: 1243
Study 25284616 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline esophageal varices
Number of subjects: 1243
Study 25284616 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time
Number of subjects: 1243
Study 25284616 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease progression
Number of subjects: 1243
Study 25284616 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior development of PVT
Number of subjects: 1243
Study 23161357 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% (1 ml kg(‐1); Group B)
Number of subjects: 60
Study 23161357 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus dexmedetomidine (1 μg kg(‐1); Group BD)
Number of subjects: 60
Study 21810198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group discussed self-efficacy scores using the Long-Term Medication Behaviour Self-Efficacy Scale (LTMBSES)
Number of subjects: 54
Study 21810198 — intervention group
Group type: COMPARATOR
Intervention: Control group did not discuss self-efficacy scores
Number of subjects: 54
Study 21810198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients ≤ 55 years
Number of subjects: 54
Study 21810198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients > 55 years
Number of subjects: 54
Study 19476183 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transtibial technique
Number of subjects: 0
Study 19476183 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessory medial portal technique
Number of subjects: 0
Study 19476183 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde drilling technique
Number of subjects: 0
Study 15564698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna treatment (daily 60 degrees C far infrared‐ray dry sauna for 15 min, followed by 30 min bed rest with blankets, for 5 days per week for 2 weeks)
Number of subjects: 30
Study 15564698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna treatment
Number of subjects: 30
Study 15564698 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (bed rest in a temperature‐controlled room at 24 degrees C for 45 min)
Number of subjects: 30
Study 10626311 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental booklet (The Back Book)
Number of subjects: 162
Study 10626311 — intervention group
Group type: COMPARATOR
Intervention: Traditional booklet
Number of subjects: 162
Study 7717598 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg-800 mg orally twice a day on a thrice weekly regimen)
Number of subjects: 230
Study 7717598 — intervention group
Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly)
Number of subjects: 230
Study 7717598 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 230
Study 7717598 — intervention group
Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine
Number of subjects: 230
Study 7717598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 230
Study 2288407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg famotidine
Number of subjects: 107
Study 2288407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg famotidine
Number of subjects: 107
Study 2288407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg famotidine
Number of subjects: 107
Study 2288407 — intervention group
Group type: COMPARATOR
Intervention: No famotidine (control group)
Number of subjects: 107
Study 7225272 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia
Number of subjects: 20
Study 7225272 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia
Number of subjects: 20
Study 30900916 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kVp CT with 60 mL of CM
Number of subjects: 80
Study 30900916 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp CT with 100 mL of CM
Number of subjects: 80
Study 30900916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (70 kVp and 120 kVp)
Number of subjects: 80
Study 29054980 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching (EMT) intervention with parent training
Number of subjects: 97
Study 29054980 — intervention group
Group type: COMPARATOR
Intervention: Usual community treatments
Number of subjects: 97
Study 29054980 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of children with receptive-expressive language delays
Number of subjects: 97
Study 27863271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring (15mcg ethinyl estradiol and 120mcg etonogestrel per day for 84 days)
Number of subjects: 60
Study 27863271 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal oral pill (30mcg ethinyl estradiol and 150mcg levonorgestrel for 84 days)
Number of subjects: 60
Study 27863271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring
Number of subjects: 60
Study 27863271 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal oral pill
Number of subjects: 60
Study 24696010 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate, 0.05%, ointment applied once daily for 3 months
Number of subjects: 30
Study 24696010 — intervention group
Group type: COMPARATOR
Intervention: UV‐A1 phototherapy (50 J/cm²) performed 4 times weekly for 3 months
Number of subjects: 30
Study 22978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cineole (200 mg, three times per day for 6 months)
Number of subjects: 247
Study 19274793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with multivitamins (MVP)
Number of subjects: 80
Study 19274793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition exposed to light
Number of subjects: 80
Study 19274793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with trace elements (TEs)
Number of subjects: 80
Study 19274793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (all groups)
Number of subjects: 80
Study 17525141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose >8 mmol/l) in lacunar stroke
Number of subjects: 1375
Study 17525141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose >8 mmol/l) in non-lacunar stroke
Number of subjects: 1375
Study 15249353 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI) only
Number of subjects: 9434
Study 15249353 — intervention group
Group type: COMPARATOR
Intervention: Diabetes only
Number of subjects: 9434